(Q38194114)

30 August 2017

1 reference

title

QVA149 (indacaterol/glycopyrronium fixed-dose combination): a review of its use in patients with chronic obstructive pulmonary disease (English)

1 reference

chronic obstructive pulmonary disease

30 August 2017

main subject

1 reference

James E Frampton

1

1 reference

30 August 2017

publication date

1 March 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

74

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

465-488

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-014-0194-8

30 August 2017

exact match

0 references

cites work

Indacaterol: a review of its use as maintenance therapy in patients with chronic obstructive pulmonary disease

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Inhaled glycopyrronium bromide: a review of its use in patients with moderate to severe chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Efficacy and safety of QVA149 compared to the concurrent administration of its monocomponents indacaterol and glycopyrronium: the BEACON study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

The Influence of receptor kinetics on the onset and duration of action and the therapeutic index of NVA237 and tiotropium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Use of indacaterol for the treatment of COPD: a pharmacokinetic evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Safety and efficacy of dual bronchodilation with QVA149 in COPD patients: the ENLIGHTEN study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol-fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE): a randomised, double-blind, parallel group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Minimal clinically important differences in COPD lung function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Outcomes for COPD pharmacological trials: from lung function to biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Minimal clinically important differences in pharmacological trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

The MCID of the transition dyspnea index is a total score of one unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Effectiveness of smoking cessation interventions among adults: a systematic review of reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Diagnosis and Management of Stable Chronic Obstructive Pulmonary Disease: A Clinical Practice Guideline Update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Current and novel bronchodilators in respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

A multivalent approach to the discovery of long-acting β(2)-adrenoceptor agonists for the treatment of asthma and COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Pharmacological characterization of abediterol, a novel inhaled β(2)-adrenoceptor agonist with long duration of action and a favorable safety profile in preclinical models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Aclidinium bromide: an alternative long-acting inhaled anticholinergic in the management of chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Muscarinic receptors on airway mesenchymal cells: novel findings for an ancient target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Indacaterol/glycopyrronium bromide fixed-dose combination for the treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Long-acting muscarinic receptor antagonists for the treatment of respiratory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Effects of inhaled corticosteroids in monotherapy or combined with long-acting {beta}2-agonists on mortality among patients with chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Long-acting beta-agonists and their association with inhaled corticosteroids in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

How and when to use inhaled corticosteroids in chronic obstructive pulmonary disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Safety of long-acting beta-agonists in stable COPD: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Tiotropium Respimat inhaler and the risk of death in COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Cost effectiveness of pharmacological maintenance treatment for chronic obstructive pulmonary disease: a review of the evidence and methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Cost effectiveness of therapy with combinations of long acting bronchodilators and inhaled steroids for treatment of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Tiotropium inhibits pulmonary inflammation and remodelling in a guinea pig model of COPD

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-014-0194-8

Pharmacotherapies for COPD.

21 January 2018

1 reference

12 December 2020

Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study

1 reference

12 December 2020

Efficacy and safety characteristics of mometasone furoate/formoterol fumarate fixed-dose combination in subjects with moderate to very severe COPD: findings from pooled analysis of two randomized, 52-week placebo-controlled trials

1 reference

12 December 2020

Inhaled corticosteroids for stable chronic obstructive pulmonary disease

1 reference

12 December 2020

Pharmacological treatment of chronic obstructive pulmonary disease

1 reference

12 December 2020

Safety, tolerability and pharmacokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD.

1 reference

12 December 2020

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: the BRIGHT study

1 reference

12 December 2020

St. George's Respiratory Questionnaire: MCID

1 reference

12 December 2020

Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison

1 reference

12 December 2020

Bronchodilator combinations for COPD: real hopes or a new Pandora's box?

1 reference

12 December 2020

Efficacy and safety of indacaterol 150 microg once-daily in COPD: a double-blind, randomised, 12-week study

1 reference

12 December 2020

Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study.

1 reference

12 December 2020

Influencing the decline of lung function in COPD: use of pharmacotherapy

1 reference

12 December 2020

Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease

1 reference

12 December 2020

Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial

1 reference

12 December 2020

COPD exacerbation frequency, pharmacotherapy and resource use: an observational study in UK primary care

1 reference

12 December 2020

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease

1 reference

12 December 2020

10.1007/S40265-014-0194-8

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1023376032

0 references

1 reference